Sentences with phrase «of vaccine antigens»

The service «Expression of vaccine antigens in plant - based systems» can be requested as a standalone service, or in the context of the «Cross-platform screening and optimization service» which enabled the user to have vaccine antigens expressed in several different platforms with the aim to compare yields, integrity and (if possible) functionality of the protein when produced in different systems.

Currently, pDNA can be used directly as a therapeutic agent (e.g., in gene therapy or generation of vaccine antigens) and indirectly for a range of applications.

«It also led to an increase in both antibiotic susceptibility and the formation of membrane vesicles containing greater amounts of vaccine antigens.»

This service will allow users to improve the compatibility and stability of their vaccine antigen with different mucosal adjuvants (from the HZI portfolio) and to define the optimal production methods to generate immunogenic vaccine candidates with optimised physicochemical stability (in vitro studies).

Using so called calibration - free concentration analysis (CFCA) it is usually possible to address the total concentration of vaccine antigen specific antibodies in serum samples.

Not exact matches

are made with reduced quantities of the same antigens that are in the Infanrix DTaP vaccine that many kids already get

Secondly, it helps improve the immunogenicity of some vaccines, which is the body's ability to produce antibodies against the antigen for which the vaccine has been given.

Bringing back the whole - cell vaccine is unlikely, Edwards and Offit say, because of the safety concerns, but Edwards suggests it might be possible to modify a new whole - cell vaccine that's less reactive or to add antigens to the acellular vaccine.

In most modern vaccines, antigens come in the form of bits of deactivated virus.

Because many of these genetically modified vaccines are meant to be eaten, it can be difficult to regulate exactly how much antigen a half - cup of potato or a handful of peanuts delivers.

«Using protein engineering tools, we can look at a million or a billion variants of an antigen and pull out variants that we think would make a better vaccine,» says Ackerman.

The study size requires screening about 10,000 patients for the presence of the MAGE - A3 antigen that the vaccine targets.

The United States, for example, ordered $ 649 million of pandemic H1N1 influenza vaccine antigen and $ 283 million of adjuvant on May 22, 2009.

«Mechanism for inducing memory B cell differentiation elucidated: Efficient induction of immune cells that remember antigens will lead to the development of new vaccines.»

Vaccine researchers typically start with antigens — in this case, pieces of HIV — and then evaluate the antibodies they elicit.

In addition, the assessment of potential interference with DTaP and other vaccine antigens administered during infancy will require large prospective studies.

Known as the Fluzone High - Dose vaccine, and made by Sanofi Pasteur, the inactivated influenza vaccine contains four times the amount of antigen that is contained in the standard - dose Fluzone vaccine.

The Cancer Vaccine Collaborative is working on treatments that target multiple cancer antigens, which should trigger a more aggressive immune response and increase the odds of defeating tumors.

By better understanding how antigen presentation is translated into long - term immunity, immunologists can inform the design of simpler vaccines.

To create a diabetes vaccine, Santamaria has attached a cocktail of antigens from pancreatic beta cells to synthetic iron oxide nanoparticles.

The study included 124 newly diagnosed patients at 25 clinical trial sites in the U.S. Two - thirds of the patients were treated with ICT - 107, an experimental vaccine based on immune system cells called dendritic cells that were exposed to six synthetic proteins, or antigens, known to be involved in GBM development.

This «suggests that antibodies specific for this conserved region could provide protection against multiple toxin - mediated clostridium infections and points to a generalizable strategy for generating safe vaccine antigens for this class of toxins,» they concluded.

Principal Investigator John Morris, MD, clinical co-leader of the Molecular Therapeutics and Diagnosis Program for the CCC, co-leader of the UC Cancer Institute's Comprehensive Lung Cancer Program, professor in the division of hematology oncology at the UC College of Medicine and UC Health medical oncologist, says a number of antitumor vaccines have shown promise for causing immune responses against tumor antigens to improve patient outcomes.

To develop an effective vaccine, it is imperative to identify a suitable antigen structure of the virus which will create an effective immune response in humans.

Total vaccine supply will depend on several other unknowns, including whether 15 micrograms of antigen is enough — as is the case with seasonal vaccine — and whether one or two shots are needed.

Future work in this area will lead to a better understanding of vaccine immunology and how pregnant women respond to antigen exposure through the course of pregnancy.

While the 3D injectable scaffold is being tested in mice as a potential cancer vaccine, any combination of different antigens and drugs could be loaded into the scaffold, meaning it could also be used to treat infectious diseases that may be resistant to conventional treatments.

Compared to a bolus injection containing the same drugs and antigens (but no scaffold), the 3D vaccine was more effective at preventing tumor growth, with 90 % of mice receiving the 3D vaccine still alive at 30 days compared with only 60 % of mice given the bolus injection.

A large, randomized clinical trial tested whether a flu vaccine with four times the antigen of a standard vaccine could reduce the risk of hospitalization among those especially vulnerable seniors.

Initially, all of the makers of inactivated vaccine had trouble with the «potency assay» used to ensure that 15 micrograms of influenza antigens are present in each dose.

The researchers also identified a way to remove the problematic GlcNAc sugar so that a mutant form of the bacteria with only rhamnose - containing GAC could be purified and tested as a vaccine antigen.

Researchers plan to assess the new modified antigen against other candidates in advanced strep throat vaccine tests in nonhuman primates beginning later this year in Atlanta, Georgia, funded by the National Health and Medical Research Council of Australia.

Nirbhay Kumar, a molecular biologist at the Johns Hopkins School of Public Health in Baltimore, wondered whether injecting the genes for the Plasmodium antigens would work as a vaccine.

The current acellular vaccine, purified down to three antigens, was introduced in 1997 to replace the previous whole - cell vaccine, after side effects such as fever and crying dissuaded many parents from starting or completing the three doses of vaccine required by six months of age.

Together with a partner from the industry, the research team successfully tested a vaccine from a new AAV mimotope library for a tumour antigen of breast cancer, the growth factor HER2.

A child's immune system must cope with thousands of foreign antigens each day, whereas the 2014 recommended vaccine schedule exposes a child to only about 300 antigens by the age of 2, according to CDC.

Now scientists are able to get the antibodies they specifically desire by using nanoparticles that connect antigens, the active parts of a vaccine, with molecules that stimulate the immune system.

Cornell and Ludwig Institute for Cancer Research scientists have developed a way to produce a protein antigen that may be useful as vaccine for schistosomiasis — a parasitic disease that infects millions of people, mostly in tropical and subtropical climates — according to new research in the journal Protein Expression and Purification, June 2017.

«In addition, our method offers the potential to accelerate the development of new vaccines by allowing the efficient evaluation of candidate target antigens.»

The laboratory has also all of the technologies required to produce recombinant bacteria expressing vaccine antigens to be used as non-pathogenic vaccine vectors.

Commercial arrays are not available for all biomarkers, so customised arrays for the analysis of vaccine candidates will be developed, featuring antigens for direct detection or antibodies for sandwich immunoassays (e.g. for cytokine detection).

TNA4: Production of recombinant antigens and final formulated vaccines for toxicological studies

The symposium features presentations by Philippa Marrack and John Kappler talking on the T cell repertoire; William Paul on interleukin 4 as a prototypic immunoregulatory cytokine; Timothy Springer on lymphocyte trafficking; Pamela Bjorkman on structural studies of MHC and MHC - related proteins, and Jack Strominger on peptide presentation by class I and II MHC proteins; Thierry Boon on genes coding for tumor rejection antigens, including the first tumor antigen, MAGE - 1; and Philip Greenberg on the modification of T cells for adoptive therapy by retroviral - mediated gene insertion Since then, the symposia series has attracted leading immunologists in the cancer vaccine and antibody fields, providing them with a comprehensive view of the promises and challenges in the development of cancer immunotherapies.

In vitro reconstitution of B cell receptor - antigen interactions to evaluate potential vaccine candidates.

Cyclophosphamide, doxorubicin, and paclitaxel enhance the antigen - specific anti-tumor immune response of GM - CSF - secreting whole cell vaccines in tolerized mice.

Research will aim to improve the predictive value of animal models for vaccine evaluation, provide consultancy on the selection of appropriate models, and develop innovative approaches to characterise in vivo antigen behaviour and host responses whilst reducing animal use.

Firstly, it will develop optimised viral vectors suitable for expressing antigens from a range of different diseases, to create novel vaccines.

These assays can be used to address the qualitative and quantitative properties of vaccine candidates by analysing (i) the vaccine candidate itself and (ii) antigen - specific immune responses in the serum of patients or immunised animals.

Formulation studies, including optimisation of adjuvanted vaccine candidates, stability studies, and the development of analytical methods to characterise antigen - adjuvant combinations

After birth, the infant is immunized with a series of standardized vaccines, and exposed to a wide array of environmental antigens.